Antimicrobial susceptibility pattern of genital Mycoplasmas among a group of pregnant women  by Abdel Rahman, Safaa M. et al.
Alexandria Journal of Medicine (2016) 52, 353–358HO ST E D  BY
Alexandria University Faculty of Medicine
Alexandria Journal of Medicine
http://www.elsevier.com/locate/ajmeAntimicrobial susceptibility pattern of genital
Mycoplasmas among a group of pregnant women* Corresponding author at: Department of Medical Microbiology and Immunology, Faculty of Medicine, Ain Shams University, Al-Ab
Cairo 11591, Egypt. Tel.: +20 111 864 864 2, +20 10 18 06 15 15.
E-mail addresses: drsafaa_abdelrahman@yahoo.com (S.M. Abdel Rahman), rania_ahmedhasan@yahoo.com, rania_ahmedhasan@m
edu.eg (R.A. Hassan), noha2877@yahoo.com (N.A. Sakna).
Peer review under responsibility of Alexandria University Faculty of Medicine.
http://dx.doi.org/10.1016/j.ajme.2015.12.005
2090-5068  2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Safaa M. Abdel Rahman a, Rania A. Hassan a,*, Noha A. Sakna baDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
bDepartment of Gynaecology and Obstetrics, Ain Shams University, Cairo, EgyptReceived 10 October 2015; revised 27 November 2015; accepted 23 December 2015
Available online 17 February 2016KEYWORDS
Genital Mycoplasmas;
Mycoplasma hominis;
Ureaplasma urealyticum;
Mycoplasma IES kit;
Antimicrobial susceptibilityAbstract Mycoplasma hominis (MH) and Ureaplasma urealyticum (UU) are important members of
genital Mycoplasmas. They are implicated in urogenital infections and complicated pregnancy
(chorioamnionitis, preterm delivery, abortion, and preterm birth) as well as bacterial vaginosis
and cervicitis. The administration of antimicrobial agents to pregnant women with preterm rupture
of the membranes (PROM) may extend the gestation period and decrease the risks of associated
complications and neonatal infections. Despite empirical therapy is the rule in cases suspected to
have genital infection in Egypt, the surveillance of the susceptibilities of used antibiotics is manda-
tory to ensure treatment efficacy and good prevention of any possible complications. This study
aimed to assess the infection rate of genital Mycoplasmas (MH and UU) among pregnant females
and their antimicrobial susceptibility pattern to provide a provisional idea about the effectiveness of
antibiotics used empirically to treat cases of genital infections in pregnant women. High vaginal
swabs of 50 pregnant females were examined using Mycoplasma IES kit, for identification of UU
and MH. The kit also provides the antimicrobial susceptibility results for 12 antimicrobials of five
different classes. UU and MH were detected in 26/50 (52%), and 7/50 (14%) of cases respectively,
of which 5 cases showed mixed infection with both organisms. UU was most sensitive to quinolones
(90–95%), followed by tetracyclines (80–85%). The least sensitivity was detected with chloram-
phenicol and clindamycin (40% and 30% respectively). The two MH isolates (100%) were sensitive
to the three tested quinolones in addition to clindamycin and thiamphenicol. MH showed 100%
sensitivity to clindamycin and 75% of UU isolates were sensitive to azithromycin. Further studies
are needed to detect any future changes in the susceptibility pattern for these drugs or other
antibiotics.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).baseya,
ed.asu.
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Mycoplasma hominis (MH) and Ureaplasma spp., including
Ureaplasma parvum and Ureaplasma urealyticum (UU) are col-
lectively known as genitalMycoplasmas. They are found in the
genital milieu of up to 80% of pregnant and non-pregnant
women.1
M. hominis-as a common commensal of the female genital
tract- has been associated with pyelonephritis, bacterial vagi-
nosis, cervicitis, endometritis, PID and postpartum septicemia.
U. urealyticum is considered as the main cause of non-
chlamydial, non-gonococcal urethritis, chorioamnionitis, pre-
term delivery, abortion, preterm birth, bacterial vaginosis
and cervicitis.2–4 The administration of antimicrobial agents
to pregnant women with preterm rupture of the membranes
(PROM) may extend the gestation period and decrease the
risks of associated complications and neonatal infections.5,6
Bacterial resistance to routine antimicrobial agents is a
growing and a worldwide problem. The lack of a rigid cell wall
renders genital Mycoplasmas innately resistant to antimicro-
bial agents, such as b-lactam antibiotics and vancomycin.7
Although macrolides are often the drugs of choice for treating
these infections, M. hominis is intrinsically resistant to the C14
and C15 macrolides (e.g. erythromycin and azithromycin).8
Ureaplasma species also have natural resistance to lin-
cosamides (e.g. clindamycin); observed resistance to macro-
lides is associated with mutations in the 23S rRNA gene.9,10
Mycoplasma and Ureaplasma infections are usually treated
with tetracycline, except in neonates or children – during the
first 6 years of life-in whom the drug is deposited in bony struc-
tures and teeth causing discoloration. It occurs also in new-
borns of mothers who received tetracyclines for long periods
during pregnancy. Tetracyclines may also cause hepatic dam-
age or severe vestibular toxicity. Instead, erythromycin is rec-
ommended.11 However, the amniotic sac is not effectively
penetrated by erythromycin and Ureaplasmas are not eradi-
cated from the vagina or cervix by this agent. Newer macro-
lides (e.g. azithromycin and clarithromycin) allow for better
tolerability and the once daily dosing benefit can increase com-
pliance. Treatment with azithromycin is equally successful
compared to erythromycin but with fewer side effects.6
The increase in resistance of genital Mycoplasmas to
antimicrobial agents has prompted the implementation of
ongoing surveillance studies.
2. Aim of the work
The aim of the present study was to assess the infection rate
and antimicrobial susceptibilities of these two sexually trans-
mitted pathogens M. hominis and U. urealyticum among a
group of Egyptian pregnant women attending antenatal care
clinic.
3. Subjects and methods
3.1. Subjects
This cross-sectional study included 50 pregnant females aged
>18 years, attending the antenatal care clinic – Gynecologyand Obstetrics Hospital – Faculty of Medicine – Ain Shams
University, from January 2015 to June 2015. All women
enrolled in the study gave informedwritten consent prior to their
participation. Data collected from participants included age,
gestational age, the presence or absence of any symptoms
suggesting of vaginitis (change in amount of vaginal secretion
with changing in odor or color and itchy vaginal irritation),
samples were collected and laboratory work was conducted in
Medical Microbiology and Immunology Department- Faculty
of Medicine- Ain Shams University. The only exclusion
criterion was antimicrobial intake 3 weeks prior to the sample
collection time.
3.2. Samples collection
High vaginal swabs were taken from each subject enrolled
in the study using sterile cotton swabs. Each swab was
inoculated to one diluent vial (provided by the kit). Diluent
vials were then recapped and sent to the Medical Microbi-
ology and Immunology Department laboratory for
processing.
3.3. Genital Mycoplasmas detection and antimicrobial
susceptibility testing
3.3.1. Principle of the test
Genital Mycoplasmas detection and antimicrobial susceptibil-
ity testing were done using Mycoplasma Culturing, Identifica-
tion, Enumeration, and Susceptibility Kit (Mycoplasma IES
kit – Autobio Diagnostics – China). Mycoplasma IES kit is
based on cultivation and biochemical reactions. Urea is
decomposed by the urease enzyme produced by U. urealyticum
with release of NH3. For detection of M. hominis, arginine is
decomposed by Arginase enzyme-produced by the organism-
and releases NH3. Then NH3 causes an increased pH of the
liquid medium. The corresponding color change of the indica-
tor was used to judge the result. The susceptibility strip con-
tains 12-antibiotics, each one in two concentrations Fig. 1. If
Mycoplasma was sensitive to an antibiotic, the activity of the
enzyme was inhibited causing no change in color. Types and
concentrations of tested antibiotics are summarized in Table 1.
The kit also provides further data about the detected organism
either there is colonization (<104 CFU) or infection (>104
CFU).
3.3.2. Procedure
Culture media were prepared by mixing the freeze-dried pow-
der vial (peptone of bovine origin and beef heart infusion) and
the inoculated diluent vials (both provided by the kit).
The procedure was done according to the manufacturer’s
instructions. Each inoculated diluent vial was added to one
of the freeze-dried powder vials (both were provided by the
kit). After well shaking and complete dissolution, 100 ll of
the mixture was added to each well of the strip by automatic
pipetting. Strip was then shaken gently then each well was cov-
ered with one drop of mineral oil. The strip was then covered
and incubated at 37 C for 24 h. Change in color of the well to
red color indicated positive reaction and microbial growth
Fig. 2.
Figure 1 Mycoplasma IES kit – the 12 antibiotic susceptibility test strip (colored).
Table 1 Types and concentrations of tested antibiotics.
Category Antibiotic Conc. 1
(mg/L)
Conc. 2
(mg/L)
Tetracyclines Minocycline (MIN) 2 8
Doxycycline (dox) 4 8
Macrolides Roxithromycin
(ROX)
1 4
Erythromycin
(ERY)
2 8
Azithromycin
(AZI)
1 4
Clarithromycin
(CLA)
2 8
Josamycin (JOS) 2 8
Chloramphenicols Thiamphenicol
(THI)
2 8
Lincosamides Clindamycin (CLI) 1 4
Quinolones Sparfloxacin (SPA) 1 4
Levofloxacin
(LEV)
1 4
Gatifloxacin
(GAT)
1 4
Table 2 Demographic data and infection percentage among
the studied cases.
Parameters
Age (mean ± SD): 25.3 ± 4.99
Gestational age (mean ± SD): 25 ± 6.23
Ureaplasma urealyticum
Number (%)
Colonization 5 (10%) 26 (52%)
Infection 21 (42%)
Mycoplasma hominis
Number (%)
Colonization 0 (0%) 7 (14%)
Infection 7 (14%)
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The present study was conducted on 50 pregnant females
attending the antenatal care clinic of Ain Shams University
Gynecology and Obstetrics Hospital. Their ages ranged from
16 to 35 with a mean of 25.3 ± 4.99. The gestational age ran-
ged from 10 to 36 weeks with a mean of 25 ± 6.23. History ofFigure 2 Results of Mycoplasma IES kit – the 12 antibiotic suscepti
SPA, LEV and GAT; resistant to MIN, DOX, THI, CLI) (colored).symptoms suggesting for vaginal infection was recorded, and
only 10 females (20%) gave history of symptoms.
Using Mycoplasma IES kit, Out of the 50 vaginal swabs, 28
cases (56%) were positive for eitherM. hominis, U. urealyticum
or both. Of these 28 cases, 5 cases showed mixed infection of
both organisms Table 2.
26 isolates of U. urealyticum were detected (52%) of total
swabs. Among these 26 isolates positive for U. urealyticum, 5
cases (10%) represented colonization (<104 CFU), and 21
cases (42%) represented infection (>104 CFU) Table 2.
Only 7 isolates of M. hominis were detected (14%) of total
cases. The 7 cases represented infections (>104 CFU) Table 2.
No significant correlation was detected between symptoms
suggesting of genital infection and the presence of either colo-
nization, infection with U. urealyticum or infection with M.
hominis, and p values were 0.23, 0.2, and 0.68 respectively.
Antimicrobial susceptibility testing was performed by the
kit for both organisms for 12 antibiotics of 5 categories:
Macrolides [roxithromycin (ROX), azithromycin (AZI), josa-
mycin (JOS), clarithromycin (CLA), and erythromycinbility test strip (infection with UU> 104, sensitive to AZI, CLA,
Table 3 Results of antimicrobial susceptibility among isolates of both Mycoplasma hominis and Ureaplasma urealyticum.
Ureaplasma urealyticum (N= 20) Mycoplasma hominis (N= 2)
S I R S I R
Macrolides Roxithromycin (ROX) 12 (60%) 5 (25%) 3 (15%) – 1 (50%) 1 (50%)
Azithromycin (AZI) 15 (75%) 2 (10%) 3 (15%) 1 (50%) – 1 (50%)
Josamycin (JOS) 13 (65%) 5 (25%) 2 (10%) 1 (50%) – 1 (50%)
Clarithromycin (CLA) 15 (75%) – 5 (25%) 1 (50%) – 1
Erythromycin (ERY) 9 (45%) 5 (25%) 6 (30%) – 1 (50%) 1 (50%)
Quinolones Sparfloxacin (SPA) 18 (90%) 1 (5%) 1 (5%) 2 (100%) – –
Levofloxacin (LEV) 19 (95%) – 1 (5%) 2 (100%) – –
Gatifloxacin (GAT) 18 (90%) – 2 (10%) 2 (100%) – –
Tetracyclines Doxycycline (dox) 16 (80%) 2 (10%) 2 (10%) 1 (50%) 1 (50%) –
Minocycline (MIN) 17 (85%) 1 (5%) 2 (10%) 1 (50%) 1 (50%) –
Chloramphenicol Thiamphenicol (THI) 8 (40%) 7 (35%) 5 (25%) 2 (100%) – –
Lincosamides Clindamycin (CLI) 6 (30%) 2 (10%) 12 (60%) 2 (100%) – –
356 S.M. Abdel Rahman et al.(ERY)], quinolones [sparfloxacin (SPA), levofloxacin (LEV),
gatifloxacin (GAT)], tetracyclines [doxycycline (DOX),
minocycline (MIN)], chloramphenicols [thiamphenicol
(THI)], and lincosamides [clindamycin (CLI)].
Antimicrobial susceptibility testing could not be done to the
isolates from the five cases of mixed infection. Susceptibility
testing results could not be read clearly in one out of the 21 iso-
lates of U. urealyticum, which may be due to the low organism
load in this case. Table 3 shows the results of antimicrobial
sensitivity of the 20 isolates of UU and 2 isolates of MH.
The results of antimicrobial sensitivity testing revealed that
UU isolates were most sensitive to the tested quinolones with
sensitivity rates 90%, 95% and 90% for sparfloxacin, levoflox-
acin and gatifloxacin respectively. This was followed by
tetracyclines with sensitivity rates of 80% and 85% for doxy-
cycline and minocycline respectively. Regarding the group of
tested macrolides, the sensitivity rates ranged from 45% for
erythromycin and 75% for azithromycin and clarithromycin.
The least sensitivity rates were for clindamycin (30%) and thi-
amphenicol (40%).
For the isolates of MH, the 2 isolates (100%) were sensitive
to the 3 tested quinolones in addition to clindamycin and
thiamphenicol.
5. Discussion
M. hominis, U. urealyticum and Mycoplasma genitalium are the
mollicutes (class of bacteria lacking cell walls) most frequently
isolated in the genital tract and the most potentially patho-
genic. They are associated with pelvic inflammatory disease,
urethritis, salpingitis, bacterial vaginosis, infertility, ectopic
pregnancy, obstetric pathologies (spontaneous abortion, pre-
term delivery and puerperal infections) as well as perinatal dis-
orders (low birth weight, respiratory and neurological
infections).12 Culture of Mycoplasma is labor intensive and
time consuming, as it requires the use of an enrichment broth
for up to seven days, followed by sub-culturing on solid media.
Analytical sensitivities in the range of 60% are only obtained
in skilled laboratories and identification is restricted to the
genus level. The development of commercially available
diagnostic assays, which are based on liquid broth culturesprovides easy to use and faster alternatives to conventional
culture methods for the detection of genital Mycoplasmas.13
In the present study, identification and antimicrobial suscepti-
bility testing of genitalMycoplasmas were performed using the
Mycoplasma Culturing, Identification, and Enumeration, Sus-
ceptibility Kit (Mycoplasma IES kit) as a rapid and simple
phenotypic based diagnostic method.
In the present study, 26 isolates of U. urealyticum were
detected in 26 out of 50 samples (52%), while M. hominis
was only isolated from 7 (14%) of the samples, of which 5
(10%) isolates were mixed with UU; similar to our results
Zhu et al.14 in their study reported an overall positive incidence
of genitalMycoplasmas of 62.16%. The most common pattern
was UU monoinfection (46.52%), the UU–MH coinfection
pattern ranked second (13.91%) and MH monoinfection was
the lowest (1.71%).
The prevalence of genitalMycoplasmas varied widely in dif-
ferent reports. In a study by Sobouti et al.15, vaginal colonization
among a group of recent mothers was found to be 15%
(25/165) for U. urealyticum and 15% (25/165) for M. hominis.
A lower percentage was reported by Bayraktar et al.1 who
examined samples from one hundred pregnant women, they
successfully cultured M. hominis in five women (5%) and
U. urealyticum in 27 (27%), and they reported simultaneous
colonization with both M. hominis and U. urealyticum in 6%
of symptomatic patients.
A higher rate of detection of both organisms was reported
by Redelinghuys et al.6, and they found that 76% (73/96) of
specimens contained Ureaplasma spp., with also a higher per-
centage of simultaneous colonization with M. hominis [39.7%
(29/73)].
In a study by Kechagia et al.8 U. urealyticum was grown as
a single pathogen in 65 (47.44%) out of specimens, while M.
hominis was grown as a single pathogen in 0.72% and in
2.92% both urogenital Mycoplasmas were grown.
Earlier studies reported colonization rate with U. ure-
alyticum ranging between 10% and 50% of women, and colo-
nization rates with M. hominis of less than 30%.16,17
The discrepancy in prevalence rates can be attributed to the
different study populations and the different detection meth-
ods.12 The type of assay may have an effect on the accurate
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factors and antimicrobial agents included in the media of the
commercial assay.13
Using quantitative PCR by Campos et al.18 increased the
isolation rate of M. hominis and M. genitalium to 31.8% and
28.1%, respectively, also using multiplex PCR increased the
detection rate of genital Mycoplasmas up to 84% (185/220)
as reported by Redelinghuys et al.19
In the present study, no significant correlation was deter-
mined between the detection of genital Mycoplasma and the
symptoms of the cases. This is similar to the results of
Redelinghuys et al.6 as they reported that symptoms were
vague and subjective and did not correlate with the study
results, and the women could not definitely distinguish
between a physiological discharge and an unusual vaginal
discharge.
Although agar and broth dilution methods may be used to
determine antibiotic susceptibilities, the complex growth
requirements of Mycoplasmas have restricted their perfor-
mance.20 In the present study, theMycoplasma IES kit showed
that UU isolates were most sensitive to the tested quinolones
with sensitivity rates 90–95%, followed by tetracyclines with
sensitivity rates of 80% and 85%. Regarding the group of
tested macrolides, the sensitivity rates ranged from 45% for
erythromycin to 75% for azithromycin and clarithromycin.
The least sensitivity rates were for clindamycin (30%) and thi-
amphenicol (40%).
There was a wide range of variability in the results of
antimicrobial sensitivity of different antimicrobial categories.
In agreement with our results, Redelinghuys et al.6 reported
susceptibilities of Ureaplasma spp. to levofloxacin and moxi-
floxacin of 59% (26/44) and 98% (43/44) respectively. In addi-
tion, Krausse and Schubert21 reported that Ofloxacin was
effective against U. urealyticum (>95% susceptibility), but
ciprofloxacin was less active with a sensitivity of 35.2%.
In contrast to the results of the present study, Bayraktar
et al.1 found the highest drug resistance rates in U. urealyticum
were 92.6% to ciprofloxacin and 85.2% to ofloxacin. In
another study, Leli et al,22 found that 66.4% (101/152) of
U. urealyticum isolates were resistant to ciprofloxacin, whereas
27.6% (42/152) were resistant to ofloxacin. In addition,
Kechagia et al.8, in their work found that ciprofloxacin and
ofloxacin were inactive against most of the isolated strains.
Despite the high sensitivity of quinolones reported in the
present study, Fluoroquinolones are classified as category C
agents and the use of these agents in pregnancy is
controversial.6,23
Similar to the results of the present study regarding sensitiv-
ity to tetracyclines, Kechagia et al.8 found that 87.4% and
98.2% of the isolated U. urealyticum strains were susceptible
to tetracycline and doxycycline, respectively. Tetracyclines
were also most effective against isolated U. urealyticum (sensi-
tivity rates of 81–100%) according to Koh et al.24, Bayraktar
et al.1, Krausse and Schubert21, and Leli et al.22
In contrast to these results, Redelinghuys et al.6 reported
the susceptibility of Ureaplasma isolates to tetracycline was
found to be 27%.
Regarding sensitivity to macrolides, Krausse and Schu-
bert21, and Bayraktar et al.1 reported a very high sensitivity
of U. urealyticum isolates especially to josamycin which is a
novel drug. However, in the study of Kechagia et al.8 they
reported that only 79.2% of isolates were susceptible tojosamycin, while erythromycin and azithromycin, proved to
be inactive against most of the strains.
The use of erythromycin in pregnant women has permitted
the surveillance of long-term effects of this antimicrobial
agent. These include infantile hypertrophic pyloric stenosis,
cardiac toxicity and maternal hepatotoxicity. There is not
enough data available to know whether the risks of toxicity
in neonates are similar with newer macrolide antimicrobial
agents. It was suggested that if the price of azithromycin in
many countries decreases to an affordable level, it might
potentially replace erythromycin as a general treatment option
in the future. The treatment options of genitalMycoplasmas in
pregnancy therefore remain limited.7,6
In the present work, the 2 isolates of M. hominis (100%)
were sensitive to the 3 tested quinolones in addition to clin-
damycin and thiamphenicol, and other drugs showed 0% or
50% sensitivity. In agreement with our results, Bayraktar et al.1
reported thatM. hominis was more sensitive to quinolones and
naturally resistant to erythromycin. In contrast to our results,
they also reported a potent activity of josamycin against M.
hominis.
Similarly, Bayraktar et al.1 found that among M. hominis,
the highest drug resistance rate was 100% to erythromycin,
while No resistance was observed to josamycin, although some
strains had intermediate resistance.
Different results were reported by Kechagia et al.8 who
found that M. hominis isolates were 100% susceptible to tetra-
cycline, doxycycline and pristinamycin, while susceptibilities to
the other antimicrobial agents varied mainly in the range of
‘intermediate’ or ‘resistant’.
Krausse and Schubert21 in their study reported that doxy-
cycline was the most active tetracycline against M. hominis,
with resistance rate approximately 10–13%. Ofloxacin was
also effective (>95% susceptibility). Ciprofloxacin was moder-
ately active against M. hominis (70.3% susceptibility). The
wide range of variability in the antimicrobial susceptibility
patterns can be attributed to the different antimicrobial-use
policies, which lead to the emergence of resistance to one or
other antimicrobial group. Other variables contributing to this
discrepancy might include the population studied, the study
period, or the kits used for specimen processing and analyses.6
Although this research involves a short study period and
does not include a representative population sample (its main
limitations), to our knowledge it is the first study carried out
locally in Gynecology and Obstetrics Hospital – Faculty of
Medicine – Ain Shams University on this topic. Thus, further
research is needed to see whether these results hold for the lar-
ger population; such research will require a larger sample size
and full access to clinical, epidemiological and microbiological
variables. In the present study, MH showed 100% sensitivity
to clindamycin and 75% of UU isolates were sensitive to azi-
thromycin. Both drugs are used empirically during pregnancy.
Further studies are recommended to detect any changes in the
susceptibility pattern for these drugs or other antibiotics that
will affect the effectiveness of treatment.6. Conclusions
Despite empirical therapy is important in the treatment of
Mycoplasmas, the discrepancies in antimicrobial sensitivity
patterns in different countries make it uncertain to establish
358 S.M. Abdel Rahman et al.common guidelines for the empirical treatment of genital
Mycoplasmal infections.
In the present study, MH showed 100% sensitivity to
clindamycin and 75% of UU isolates were sensitive to
azithromycin. Both drugs are used empirically during preg-
nancy. Further studies are recommended to detect any changes
in the susceptibility pattern for these drugs or other antibiotics
that will affect the effectiveness of treatment.
Effective treatment depends on the antimicrobial suscepti-
bilities of genital Mycoplasmas in a specific region. Routine
monitoring is mandatory to ensure the efficacy of treatment.
The implementation of rational treatment regimens that
requires the in vitro determination of the antimicrobial suscep-
tibility of the isolated genitalMycoplasmas in each clinical case
is now a simple routine laboratory procedure using commer-
cially available systems.
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